OBJECTIVES: To examine whether histamine-2 receptor antagonist medications (H2RAs) are associated with a lower incidence of all-cause dementia or Alzheimer's disease (AD), as some studies have suggested. DESIGN: Prospective population-based cohort SETTING: Group Health, an integrated health maintenance organization, Seattle, Washington. PARTICIPANTS: Two thousand nine hundred twenty-three participants aged 65 and older without dementia at baseline, with initial recruitment between 1994 and 1996. MEASUREMENTS: Follow-up occurred every 2 years to identify incident dementia and AD using standard criteria. Exposure to H2RAs was determined based on automated pharmacy data. Three aspects of exposure (time-varying) were examined based on standard daily dose (SDD): cumulative use, intensity of use (highest SDD in any prior 2-year window), and cumulative use stratified according to recency (1-3 years vs >3 years before). RESULTS: Over a mean follow-up of 6.7 years, 585 subjects developed dementia (453 developed AD). Total cumulative exposure was not associated with dementia (P=.35; omnibus test) or AD (P=.23). The adjusted hazard ratios for the highest exposure category (>1,080 SDDs) compared with light or no use were 1.28 (95% confidence interval (CI)=0.95-1.72) for dementia and 1.41 (95% CI=1.00-1.97) for AD. Intensity of use was not associated with dementia (P=.39) or AD (P=.63). Examining exposure according to recent and distant cumulative use also showed no association with dementia (P=.11) or AD (P=.30). CONCLUSION: No association was found between H2RA use and risk of all-cause dementia or AD using more-detailed and -extensive information about past H2RA use than any prior study.
OBJECTIVES: To examine whether histamine-2 receptor antagonist medications (H2RAs) are associated with a lower incidence of all-cause dementia or Alzheimer's disease (AD), as some studies have suggested. DESIGN: Prospective population-based cohort SETTING: Group Health, an integrated health maintenance organization, Seattle, Washington. PARTICIPANTS: Two thousand nine hundred twenty-three participants aged 65 and older without dementia at baseline, with initial recruitment between 1994 and 1996. MEASUREMENTS: Follow-up occurred every 2 years to identify incident dementia and AD using standard criteria. Exposure to H2RAs was determined based on automated pharmacy data. Three aspects of exposure (time-varying) were examined based on standard daily dose (SDD): cumulative use, intensity of use (highest SDD in any prior 2-year window), and cumulative use stratified according to recency (1-3 years vs >3 years before). RESULTS: Over a mean follow-up of 6.7 years, 585 subjects developed dementia (453 developed AD). Total cumulative exposure was not associated with dementia (P=.35; omnibus test) or AD (P=.23). The adjusted hazard ratios for the highest exposure category (>1,080 SDDs) compared with light or no use were 1.28 (95% confidence interval (CI)=0.95-1.72) for dementia and 1.41 (95% CI=1.00-1.97) for AD. Intensity of use was not associated with dementia (P=.39) or AD (P=.63). Examining exposure according to recent and distant cumulative use also showed no association with dementia (P=.11) or AD (P=.30). CONCLUSION: No association was found between H2RA use and risk of all-cause dementia or AD using more-detailed and -extensive information about past H2RA use than any prior study.
Authors: Susan R Heckbert; Charles Kooperberg; Monika M Safford; Bruce M Psaty; Judith Hsia; Anne McTiernan; J Michael Gaziano; William H Frishman; J David Curb Journal: Am J Epidemiol Date: 2004-12-15 Impact factor: 4.897
Authors: Yuji Okura; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Eric B Larson; Li Wang; James D Bowen; Wayne C McCormick; Linda Teri; Paul Crane; Walter Kukull Journal: Ann Intern Med Date: 2006-01-17 Impact factor: 25.391
Authors: Denise M Boudreau; Mark P Doescher; Barry G Saver; J Elizabeth Jackson; Paul A Fishman Journal: Pharmacoepidemiol Drug Saf Date: 2005-12 Impact factor: 2.890
Authors: E L Teng; K Hasegawa; A Homma; Y Imai; E Larson; A Graves; K Sugimoto; T Yamaguchi; H Sasaki; D Chiu Journal: Int Psychogeriatr Date: 1994 Impact factor: 3.878
Authors: J C Breitner; K A Welsh; M J Helms; P C Gaskell; B A Gau; A D Roses; M A Pericak-Vance; A M Saunders Journal: Neurobiol Aging Date: 1995 Jul-Aug Impact factor: 4.673
Authors: Shelly L Gray; Rod L Walker; Sascha Dublin; Onchee Yu; Erin J Aiello Bowles; Melissa L Anderson; Paul K Crane; Eric B Larson Journal: J Am Geriatr Soc Date: 2017-11-14 Impact factor: 5.562
Authors: Paul Lochhead; Kaitlin Hagan; Amit D Joshi; Hamed Khalili; Long H Nguyen; Francine Grodstein; Andrew T Chan Journal: Gastroenterology Date: 2017-07-18 Impact factor: 22.682
Authors: Che-Yuan Wu; Lisa Y Xiong; Michael Ouk; Jennifer S Rabin; Nathan Herrmann; Krista L Lanctôt; Moira K Kapral; Marcus Law; Hugo Cogo-Moreira; Jodi D Edwards; Walter Swardfager Journal: Alzheimers Dement (N Y) Date: 2022-02-10
Authors: Rachel M Shaffer; Magali N Blanco; Ge Li; Sara D Adar; Marco Carone; Adam A Szpiro; Joel D Kaufman; Timothy V Larson; Eric B Larson; Paul K Crane; Lianne Sheppard Journal: Environ Health Perspect Date: 2021-08-04 Impact factor: 9.031